Abstract Background: In patients receiving anti‐cancer treatment, cachexia results in poorer oncological outcomes. However, there is limited understanding and no…
Abstract Significant variation exists in the outcomes used in cancer cachexia trials, including measures of body composition, which are often…
Abstract The use of patient‐reported outcomes (PROMs) of quality of life (QOL) is common in cachexia trials. Patients’ self‐report on…
Abstract There is no consensus on the optimal endpoint(s) in cancer cachexia trials. Endpoint variation is an obstacle when comparing…